Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US.

作者：Mairead Kearney, Hamid Mahmoudpour, Chiemeka Ike, Ambar Modh, Sebastian Monzon, Matina Fragkogianni, Ken Carson · 发表于：Journal of Clinical Oncology · 年份：2023 · DOI：10.1200/jco.2023.41.6_suppl.572 · 被引用次数：5 · 研究领域：Bladder and Urothelial Cancer Treatments、Cancer Immunotherapy and Biomarkers、Urinary and Genital Oncology Studies

572 Background: Platinum-based chemotherapy (PBC) is standard first-line (1L) treatment (tx) for patients (pts) with la/mUC. On June 30, 2020, avelumab was approved in the US as 1L maintenance (1LM) for pts without disease progression following PBC. Other novel agents such as enfortumab vedotin were recently approved for second-line (2L) or later tx. Little is known about how to incorporate these agents into the optimal tx sequencing approach. This real-world (RW) study describes the characteristics and tx patterns of pts with la/mUC. Methods: A retrospective cohort of de-identified records of pts with la/mUC was obtained from the Tempus Database. Eligible pts were diagnosed with la/mUC between January 1, 2016 and February 23, 2022. Pts who completed 1L PBC were categorized as 1LM or 2L-treated. 1LM was differentiated from 2L tx based on stated clinical intent of 1LM or initiation of immunotherapy (IO) within 180 days of 1L PBC completion without disease progression. These patients were split into pre and post groups based on when they completed their 1L PBC in relation to avelumab 1LM US approval on June 30, 2020. Results: A total of 821 pts were included from community centers (21%), academic centers (27%), and ASCO CancerLinQ network sites (52%). The median age at diagnosis was 68 years (IQR, 61-75), 73% male, and 63% White. 634 (77%) pts received 1L systemic tx; of those, 62% (395/634) received PBC, 24% (155/634) received IO monotherapy, 7% (45/634) received non-PBC, and ...